https://www.selleckchem.com/pr....oducts/zilurgisertib
G-CSF seem safe and well-tolerated, although few data are available on long-term impact of use of G-CSF.Breast cancer is the most common cause of cancer-related deaths among women. There are a limited number of targeted therapies available for triple-negative breast cancer (TNBC), and chemotherapy is the mainstay of treatment. Among checkpoint inhibitors, atezolizumab is the only drug approved for PD-L1+ TNBC patients. We performed a systematic review to assess the efficacy and safety of PD-1 inhibitor pembrolizumab in tr
Like
Comment
Share
